Technology Transactions and Licensing TRANSACTIONAL

WilmerHale's Technology Transactions and Licensing lawyers leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.


In the highly competitive worlds of biotechnology and information technology, licensing transactions and strategic alliances can make the difference between success and failure. The attorneys in WilmerHale's Technology Transactions and Licensing Practice—many of whom have backgrounds in computer engineering, biochemistry, and other technical fields—collaborate closely with our corporate, licensing, intellectual property, regulatory and tax lawyers to negotiate agreements for clients across a broad spectrum of industries. They handle hundreds of complex joint ventures, strategic alliances, and outsourcing and licensing transactions each year, some of which span international borders. Their work often receives industry commendation for its significance in shaping the future of science and technology, including from U.S. News - Best Lawyers, with clients stating that the team is “highly professional and experienced” and “exceptional.”

Contacts

Sort By
Barrett, Steven D.

Steven D. Barrett

Co-Chair, Technology Transactions and Licensing Practice Group

+1 617 526 6238 (t)

steven.barrett@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Barrett, Steven D.

Steven D. Barrett

Partner

+1 617 526 6238 (t)

steven.barrett@wilmerhale.com

Braun, Martin

Dr. Martin Braun

Partner

+49 69 27 10 78 207 (t)

martin.braun@wilmerhale.com

Finkel, Robert M.

Robert M. Finkel

Partner

+1 212 295 6555 (t)

robert.finkel@wilmerhale.com

Gokhale, Ashwin

Ashwin Gokhale

Partner

+1 650 858 6071 (t)

ashwin.gokhale@wilmerhale.com

Johnson, Jeffrey P.

Jeffrey P. Johnson

Partner

+1 617 526 6394 (t)

jeff.johnson@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Partner

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Kipnis, Jason

Jason D. Kipnis

Partner

+1 650 600 5036 (t)

jason.kipnis@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Partner

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Soiffer, Ariel

Ariel Soiffer

Counsel

+1 617 526 6089 (t)

ariel.soiffer@wilmerhale.com

Experience

We represent market leaders in life sciences, technology, energy and cleantech, communications, financial services and other industries. These companies include: 

  • Cutting-edge biotech developers Agios, Epizyme, Macrogenics, Merrimack, Ophthotech and Vedanta;
  • Gene-therapy innovators Spark Therapeutics and Editas;
  • Pharmaceutical companies Bristol-Myers Squibb and Vertex;
  • Personalized medicine company Kew Group;
  • Consumer electronics companies Bose and TiVo;
  • Data analysis pioneers Cellebrite and Thasos;
  • FinTech innovators MineralTree and Qapital, as well as financial services providers American Express and MFS Investment Management;
  • Hardware developers and manufacturers Analog Devices and SanDisk;
  • Software and IT developers Toyota InfoTechnology Center and Progress Software;
  • Telecommunications leaders Altiostar, Broadcom and Cincinnati Bell;
  • Healthcare IT innovator Caradigm;
  • Video game developer Harmonix;
  • Artificial intelligence developer MetaMind Entertainment; and
  • Filmmaking and technology company Wymsee.

Read more about the transactions we've done.

Publications & News

View

March 20, 2018

WilmerHale Counsels Vividion in Strategic Research Collaboration with Celgene

Vividion Therapeutics, a biotechnology company using novel proteomics and chemistry platforms, has announced that it entered into a strategic research collaboration with Celgene Corporation and will receive $101 million in upfront and equity consideration.

March 14, 2018

WilmerHale Counsels Voyager Therapeutics in Global Strategic Collaboration with AbbVie

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, and AbbVie, a global biopharmaceutical company, announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

February 7, 2018

Law360 Names WilmerHale a Technology Group of the Year for Second Consecutive Year

The firm has been recognized for the second consecutive year by Law360 as a Technology Practice Group of the Year for its knowledge and ability to serve the vast needs of today's most innovative technology companies.

January 29, 2018

HSR Size of Transaction Threshold to Increase to $84.4 Million

The Federal Trade Commission ("FTC") announced revised thresholds for merger notifications under the Hart-Scott-Rodino ("HSR") Act.

January 26, 2018

WilmerHale Represents Spark Therapeutics in Licensing and Supply Agreement With Novartis

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States.

December 15, 2017

WilmerHale Reps Decibel Therapeutics in Strategic Collaboration With Regeneron

On November 29, 2017, Regeneron Pharmaceuticals, Inc. and Decibel Therapeutics, Inc. announced a collaboration to discover and develop new potential therapeutics to protect, repair and restore hearing.

December 5, 2017

Astellas Acquires Mitobridge Under Existing Collaboration

Astellas Pharma Inc. and Mitobridge, Inc. announced that Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement.

November 7, 2017

LMG Life Sciences 2017 Honors WilmerHale With Top Rankings

LMG Life Sciences has recognized WilmerHale among the nation's leading life sciences law firms in its 2017 rankings, citing the firm's Life Sciences Practice as “renowned for its range and multidisciplinary teams that counsel clients in technology, pharmaceutical and medical device companies as well as investment banks and venture capitalists.”

November 1, 2017

WilmerHale Honored Throughout 2018 U.S. News - Best Lawyers® Best Law Firms List, Named Intellectual Property Litigation Firm of the Year

WilmerHale has been recognized among the 2018 U.S. News and World Report and Best Lawyers® list of Best Law Firms, an honor it has earned since the inception of these rankings in 2010.

October 26, 2017

WilmerHale Reps MacroGenics in Global Collaboration and Licensing Agreement With Incyte

MacroGenics, Inc. and Incyte Corporation announced that they have entered into an exclusive global collaboration and license agreement for MacroGenics' MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).

Recognition

  • Best Lawyers in America – Recognized 107 WilmerHale partners for 2018, naming nine as "Lawyers of the Year," including Amy Null as Boston Employee Benefits Law Lawyer of the Year, Steve Singer as New York Corporate Law Lawyer of the Year, David Westenberg as Boston Technology Law Lawyer of the Year and Jonathan Wolfman as Corporate Governance Law Lawyer of the Year. 
  • Chambers Global – Named WilmerHale among the best in the United States in outsourcing in 2014 and 2015.
  • Chambers USA: America's Leading Lawyers for Business – Named the firm in 2015-2017 among the best in Massachusetts in technology, and in 2014 among the best in the nation in outsourcing. Robert Finkel is recognized for his significant outsourcing experience, with sources saying he is “outstanding, smart, responsive and practical.” 
  • In Vivo – Named Regeneron's novel deal with Decibel Therapeutics, represented by WilmerHale, as the Top Alliance 2017 Deal of the Year.
  • Law360 – Named WilmerHale a Technology Practice Group of the Year for 2016, an award recognizing the firm's key role in the significant matters that made headlines and changed the legal landscape within the past year. 
  • LMG Life Sciences Named WilmerHale the Life Cycle Firm of the Year in 2017 and awarded the firm one of five Finance and Transactional Impact Cases of the Year for counseling Editas Medicine in its licensing and collaboration with AllerganLMG ranked the firm in its 2012-2017 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations, and previously named WilmerHale a Life Cycle Firm in 2012-2015. In 2013, WilmerHale was named the winner of the Canadian Impact Deals of the Year award, in recognition of its representation of Enobia Pharma in its acquisition by Alexion Pharmaceuticals, Inc. Co-Chairs Steven Barrett and Belinda Juran have also been named Life Sciences Stars. 
  • Super Lawyers – Named Co-Chair Steven Barrett a "Massachusetts Super Lawyer" in the areas of intellectual property and business/corporate law in the 2014-2016 editions of Boston Magazine.
  • The Legal 500 United States – Recognized Co-Chair Belinda Juran in 2013 as "a fantastic collaborator" and "outstanding in licensing."
  • U.S. News - Best Lawyers® – In the 2017 "Best Law Firms" rankings, our technology law practice was ranked in the second-tier nationally and in the first-tier in Boston. Our information technology law practice was ranked in the third-tier nationally and second-tier in Boston.
  • Who's Who Legal – Recognized Co-Chair Steven Barrett as a leader in life sciences in the 2015-2016 editions.